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Numerous studies have reported low concentrations of antituberculosis drugs in tuberculosis (TB) patients, but few studies have
examined whether low drug concentrations affect TB treatment response. We examined steady-state plasma concentrations of
isoniazid, rifampin, and pyrazinamide at 2 h after the administration of drugs (C2 h) among 181 patients with pulmonary tuber-
culosis in Indonesia and related these to bacteriological response during treatment. C2 h values below reference values for either
isoniazid, rifampin, or pyrazinamide were found in 91% of patients; 60% had at least two low C2 h concentrations. The isoniazid
C2 h was noticeably lower in fast versus slow acetylators (0.9 mg/liter versus 2.2 mg/liter, P< 0.001). At the end of treatment,
82% of the patients were cured, whereas 30 patients (17%) had dropped out during the study, and 2 patients (1%) failed treat-
ment. No association was found between C2 h concentrations and sputum culture results at 8 weeks of treatment. Post hoc analy-
sis showed that patients with low pyrazinamide C2 h (P 0.01) and patients with large extensive lung lesions (P 0.01) were at
risk of at least one positive culture at week 4, 8, or 24/32. Antituberculosis drug concentrations were often low, but treatment
response was nevertheless good. No association was found between drug concentrations and 8 weeks culture conversion, but low
pyrazinamide drug concentrations may be associated with a less favorable bacteriological response. The use of higher doses of
pyrazinamide may warrant further investigation.
Generally, first-line treatment of drug-susceptible tuberculosis(TB) is highly effective.However, a number of patients do not
respond adequately to treatment, develop drug resistance or ex-
perience a relapse of TB after completion of treatment. Inadequate
exposure to anti-TB drugs may constitute one of the factors un-
derlying suboptimal treatment response (1, 2). Among adults, low
plasma concentrations of anti-TB drugs have been found in pa-
tients with HIV infection, gastrointestinal tract disorders, high
body weight, male gender, or diabetes mellitus (DM) (3–11) and
in fast acetylators for isoniazid (12). Low plasma concentrations
can also result from interindividual variability in drug absorption,
metabolism, or excretion (3, 13). Some studies have reported as-
sociations between low concentrations of anti-TB drugs and poor
treatment response (1–3, 14), although thiswas not found in other
studies (7, 15). In a recent study performed in a preclinical model,
pharmacokinetic variability appeared to bemore important in the
emergence of multidrug-resistant tuberculosis (MDR-TB) than
nonadherence (16). Furthermore, a systematic review showed
that pharmacokinetic variability to isoniazid in multi-drug TB
regimens is significantly associated with therapy failure and ac-
quired drug resistance (17).
Nevertheless, the number of studies examining the relation
between plasma concentrations of anti-TB drugs and treatment
response remains limited and the majority of them investigated
the relation between plasma concentrations of separate anti-TB
drugs and treatment response. Therefore, in the present study, we
assessed the relation between plasma concentrations of isoniazid,
rifampin, and pyrazinamide, studied separately and in combina-
tion, in relation to treatment response in patients with pulmonary
TB. The study was a practical field pharmacokinetic study con-
ducted under routine conditions in a hospital setting in Indonesia,
which has the fourth highest case-load of TB worldwide, a high
MDR-TB burden, and cure rates between 72% (retreatment) and
91% (new smear-positive cases) (18).
MATERIALS AND METHODS
Study design and recruitment of subjects. We conducted a prospective
cohort study among TB patients who visited the Persahabatan Hospital,
Jakarta, for treatment between March 2010 and March 2011. Patients
were included if they had a positive acid-fast bacilli (AFB) smear, were
starting treatment with anti-TB drugs according to the direct observed
treatment short course (DOT) strategy, and gave informed consent. Pa-
tients who were pregnant, below 18 or above 65 years of age, with drug-
resistant isolates, or with impaired liver or renal function were excluded.
Drug dosing was according to World Health Organization (WHO)-
recommendedweight bands. Study subjects received 150, 225, 300, or 375
mg of isoniazid, 300, 450, 600, or 750mg of rifampin, and 550, 825, 1,100,
or 1,375 mg of pyrazinamide according to their body weight (the body
weight bands were 30 to 39 kg, 40 to 54 kg, 55 to 70 kg, and70 kg). The
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anti-TB drugs were administered in fixed dose combinations from Kimia
Farma that are approved by the Indonesian national program based on
bio-equivalence studies. Anti-TB drugs were taken without food.
Basic demographic and clinical information was collected from all
participants, including age, sex, body weight, and length (to calculate
body mass index [BMI]), comorbidities (including HIV infection and
DM), and concomitant drug use. HIV and DM status was checked
through blood samples collected after 4 weeks. AFB and sputum culture
were collected at baseline and at 4 weeks, 8 weeks, and 24 or 32 weeks (32
weeks for retreatment cases). Spoligotyping was performed at baseline.
Drug susceptibility testing was performed on all isolates using the propor-
tionmethod (19) in aWHO-accredited laboratory. Patients with resistant
isolateswere excluded from the study. Chest X-raysweremade at baseline,
and after 24 or 32 weeks and extensive lesions were categorized by size
(area less than 5 vertebrae, 5 to 9 vertebrae, or9 vertebrae).
Blood sampling, bioanalysis, and pharmacokinetic data analysis.
Patients had refrained from food at least 8 h before drug intake at the
pharmacokinetic sampling day. Plasma drug concentrations from blood
collected 2 h after administration of drugs (C2 h) were used as the esti-
mated peak plasma concentration (Cmax). Drug sampling took place at 4
weeks after inclusion in the study, because of the expected steady state in
the pharmacokinetics of the TB drugs at that time. In addition, 6 weeks
after inclusion in the study, full pharmacokinetic curves were obtained in
nine subjects. Serial venous blood samples were collected just before, and
at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 h after observed TB drug intake.
Plasmawas separated and stored at80°C immediately until transport on
dry ice to the Netherlands for bioanalysis. Isoniazid and acetylisoniazid
concentrations were measured with a validated method comprising liq-
uid-liquid extraction, followed by ultraperformance liquid chromatogra-
phy with UV detection. Accuracy was between 97.8 and 106.7% for iso-
niazid and between 98.0 and 108.9% for acetylisoniazid, dependent on the
concentration level. The intra- and interassay coefficients of variation
were13.4 and3.2% (dependent on the concentration) over the range
of 0.05 to 15.1 mg/liter for isoniazid, and 4.2% and 5.7% over the
range of 0.16 to 16.2 mg/liter for acetylisoniazid. Lower limits of quanti-
fication were 0.05mg/liter for isoniazid and 0.16mg/liter for acetylisonia-
zid. The concentrations of rifampin and pyrazinamide were assessed with
validated high-performance liquid chromatographic assays by methods
described previously (9). All analytical methods performed well at two
concentration levels in the first round of a recently developed interlabo-
ratory proficiency testing program for TB drugs (20). In patients with full
pharmacokinetic curves, pharmacokinetic parameters were assessed us-
ing standard noncompartmental methods in WinNonLin Version 5.3 as
described before (9).
Acetylator status for isoniazid was determined phenotypically by cal-
culating the metabolic ratio (MR) for isoniazid (acetylisoniazid C2 h/iso-
niazid C2 h), with fast acetylators having MRs 1.5 and slow acetylators
having MRs 1.5 (21).
Statistical analysis. Correlation analyses were performed for the pa-
tients with full pharmacokinetic curves to check whether C2 h was a good
representative ofCmax or total exposure (AUC0–24) for the three drugs. In
addition, independent samples t tests and correlation analyses were car-
ried out among all patients to identify determinants of pharmacokinetics
of the three different antituberculosis drugs.
The relation between plasma concentrations of antituberculosis drugs
and culture results at week 4 and 8 was explored among patients with a
positive culture at week 0. Treatment response was defined as “poor” if
patients had a positive culture at 8 weeks of treatment (22) (primary
analysis), or if patients had any positive culture at 4, 8, or 24/32 weeks of
treatment (post hoc analysis). Univariate and multivariate logistic regres-
sion analyses were used to detect determinants of poor treatment re-
sponse. Determinants evaluated were demographic variables (i.e., gender,
age, weight, and BMI), smoking, new case or retreatment case, Beijing
genotype forM. tuberculosis, comorbidities, chest X-ray findings at base-
line, sputum microscopy at baseline, and plasma concentrations of the
three TB drugs. For the plasma concentrations of each of the three TB
drugs, odds ratios (ORs) for a poor treatment response were assessed for
an interquartile range increase in C2 h, i.e., an increase in C2 h values from
the 25th percentile to the 75th percentile of the observed C2 h values (in-
terquartile OR).
C2 h values were ln transformed before statistical analysis. The multi-
variate models included C2 h of the three drugs separately, any variable
with P 0.1 in univariate analysis, DM,HIV, prior TB treatment, sputum
microscopy at baseline, andM. tuberculosis Beijing genotype. Concentra-
tions of the different drugs were not analyzed in the same model as they
were significantly correlated.
In addition to continuous measures for the C2 h values of isoniazid,
rifampin, and pyrazinamide, drug C2 h values were also examined as di-
chotomized variables based on previously published ranges forCmax (13).
These reference values represent the normal concentrations that can be
expected in adults after the standard doses of anti-TB drugs. They are
based on data that were compiled from all available sources (both healthy
volunteers and TB patients) by, among others, Holdiness (23) and Pelo-
quin (24). C2 h values were defined as low or very low, respectively, if they
were8 or4 mg/liter (rifampin),3 or1.5 mg/liter (isoniazid), and
35 or20 mg/liter (pyrazinamide). ORs for a poor treatment response
were assessed for the number of drugs (no drug, one drug, two drugs, all
three drugs) with low (or very low) concentrations in patients. All
statistical evaluations were performed with SPSS forWindows, version
16.0. P values of0.05 were considered to be statistically significant in
all analyses.
RESULTS
Patients. A total of 196 patients with pulmonary TB were re-
cruited for the study, 15 of whom were excluded from further
analysis because of missing pharmacokinetic results. The remain-
ing 181 patients presented with a 2- to 3-week history of cough
(99%), fever (67%), shortness of breath (57%), self-reported
weight loss (81%), night sweats (64%), and/or chest pain (51%)
(Table 1). The nine patients with a full pharmacokinetic curve
included in the cohort showed comparable baseline demographic
and clinical characteristics with the total cohort, although none of
the nine patients were infected with a Beijing genotype strain,
compared to 29% of the full cohort. In addition, the nine patients
had a slightly higher body weight and younger age (data not
shown). The number of fast acetylators was 5/8 (63%) among the
nine patients, compared to 98/179 (55%) among the whole co-
hort, and this affects the average pharmacokinetics of isoniazid.
Pharmacokinetics of isoniazid, rifampin, andpyrazinamide.
In the nine patients with full pharmacokinetic curves, the C2 h
values correlated well with the Cmaxs for isoniazid (Spearman’s r,
0.850; P  0.004) and pyrazinamide (Spearman’s r, 0.817; P 
0.007) but not for rifampin (Spearman’s r, 0.550; P 0.1). How-
ever, the rifampin C2 h and rifampin AUC0–24 were highly corre-
lated (Spearman’s r, 0.950; P  0.001) and similar correlations
were found for the C2 h and AUC0–24 of isoniazid (Spearman’s r,
0.967; P  0.001) and pyrazinamide (Spearman’s r, 0.700; P 
0.04).
Geometric mean (GM) C2 h values of isoniazid and rifampin
were below 3 and 8mg/liter respectively, whereas the average pyr-
azinamide C2 h values were in the reference range (Table 2).
Marked interindividual variabilitywas observed in theC2 h plasma
concentrations of the TB drugs, and low C2 h values were com-
monly observed for each of the three separate TB drugs as can be
seen in Table 2. In addition, 91% of the patients had at least one
low drug level among the three drugs and 56% of the patients had
at least one “very low” drug level. Furthermore, 60 and 11% of the
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patients had at least two lowor very lowdrug levels, respectively. A
total of 98 patients (55%) and 81 patients (45%) were classified as
fast acetylators and slow acetylators, respectively. Fast acetylators
had noticeably lower isoniazid plasma C2 h than slow acetylators
(GM, 0.9 mg/liter; interquartile range [IQR], 0.7 to 1.4 mg/liter
versus 2.2 mg/liter; IQR, 1.5 to 3.1 mg/liter; P 0.001).
Correlation analyses demonstrated that the C2 h values of the
three different drugs were significantly correlated. A higherC2 h of
rifampin correlatedwith a higherC2 h level of isoniazid (Pearson r,
0.21, P 0.004), and similar correlations were found for rifampin
and pyrazinamide (r 0.453, P 0.001) and isoniazid and pyr-
azinamide (r 0.424, P 0.001). In addition, independent sam-
ple t tests showed that patients with DM had lower isoniazid con-
centrations (GM, 1.1 versus 1.5 mg/liter, P  0.02). Other
variables, including age, body weight, BMI, and gender, did not
affect the C2 h plasma concentrations of the TB drugs.
Determinants of treatment response.Of all 181 patients, 167
(92%) had a positive culture at week 0 and were included in fur-
ther analysis. A total of 131 patients (78% of 167) had culture
results for weeks 4, 8, and 24/32. Of those, 49 (37%) had at least
one positive culture during treatment with the majority (n 38)
having a positive culture only at week 4. The proportion of pa-
tients with a positive culture decreased sharply during the course
of treatment. Fifty-six (34%) of 167 patients had a positive culture
at week 4, 11 of 155 (7%) at week 8, and 2 of 131 (2%) at weeks
24/32. After 24 or 32 weeks, the majority (149 patients or 82%) of
the 181 patients were cured, while 30 patients (17%) dropped out
during the study, and 2 patients (1%), both new smear-positive
cases, failed treatment. Of those who were cured, 140 patients
were new smear-positive cases and 9 were retreatment cases.
In primary univariate logistic regression analyses, plasma con-
centrations of the antituberculosis drugs were not significantly
associated with culture results at week 8, and none of the associa-
tions appeared to reach statistical significance either (Table 3,
lower part). For example, patients with a negative culture at week
8 (n  142) had a GM isoniazid C2 h value of 1.4 mg/liter, and
those with a positive culture (n 11) had a GM isoniazid C2 h of
1.3 mg/liter (Table 3, lower part), already indicating the lack of
TABLE 1 Demographic, clinical, and laboratory characteristics of the
study population
Characteristica
Percentage or
median (IQR)b
(n 181)
Median age in yrs 35 (25–46)
Male subjects 62.4
Diabetes mellitus 24.3
Median wt (kg) 50 (44–55)
DM 55 (47–58)
Non-DM 48 (44–53)
Median BMI 18 (17–20)
DM 21 (18–22)
Non-DM 18 (17–19)
HIV positive 1.1
Tobacco smoker 2.8
Prior TB treatment 8.8
Use of other medication 18.2
Extrapulmonary TB 4.4
Chest X-ray abnormalities
Old lesion, calcification, fibrosis 8.9
Active lesion, infiltrates, cavity 91.1
Sputum microscopy at baseline
10 AFB per 100 fields 4.4
1 to 10 AFB per field 31.5
10 AFB per field 64.1
PositiveM. tuberculosis sputum culture at baseline 92.3
M. tuberculosis Beijing genotype 29.0
Median metabolic ratio 1.9 (0.4–4.0)
Median dose (mg/kg)
Isoniazid 4.9 (4.5–5.2)
Rifampin 9.8 (9.0–10.4)
Pyrazinamide 17.9 (16.5–19.1)
a BMI, body mass index (calculated as the weight in kilograms divided by the square of
the height in meters); DM, diabetes mellitus; TB, tuberculosis; AFB, acid-fast bacilli;
metabolic ratio, calculated as acetylisoniazid C2 h divided by isoniazid C2 h; IQR,
interquartile range. Data are missing for diabetes mellitus (n 1),M. tuberculosis
Beijing genotype (n 50), and chest X-ray abnormalities (n 57).
b Data are presented as percentage or median (interquartile range).
TABLE 2 Steady-state pharmacokinetics of isoniazid, rifampin, and pyrazinamide for the nine patients with a full pharmacokinetic curve, as well as
for the total cohort
Parametera
GM (range)b
Isoniazid Rifampin Pyrazinamide
Total cohort (n 181)
C2 h GM in mg/liter (range) 1.4 (0.2–5.0) 6.5 (0.1–19.7) 36.1 (13.5–68.0)
C2 h GM in mg/liter (IQR) 1.4 (0.9–2.2) 6.5 (5.0–11.7) 36.1 (32.2–41.4)
Proportions with low C2 h levels 50% (1.5 mg/liter) 17% (4 mg/liter) 2% (20 mg/liter)
88% (3 mg/liter) 49% (8 mg/liter) 39% (35 mg/liter)
Patients with a full curve (n 9)
AUC0–24 in h · mg/liter (range) 4.4 (1.3–15.0) 35.4 (26.8–49.9) 382.4 (270.4–595.9)
Cmax in mg/liter (range) 1.9 (1.0–3.5) 9.0 (6.6–12.8) 42.3 (37.3–52.5)
Median Tmax in h (range) 1.0 (1.0) 3.0 (3.0) 1.0 (1.0)
C2 h GM in mg/liter (range) 0.9 (0.2–2.7) 6.6 (3.7–8.8) 36.2 (30.6–47.0)
C2 h GM in mg/liter (IQR) 0.9 (0.4–2.0) 6.6 (5.3–8.6) 36.2 (31.0–39.3)
Half-life in h (range) 1.9 (0.9–4.0) 1.6 (1.4–1.8) 6.7 (5.2–9.6)
a IQR, interquartile range; Cmax, maximum observed plasma concentration; Tmax, time to Cmax; AUC0–24, area under the plasma concentration-time curve from time zero until 24
h after dose administration; C2 h, plasma concentration 2 h after dose administration.
b Data are presented as the geometric mean (GM; range, minimum to maximum) except where stated otherwise. C2 h data were missing for isoniazid (n 2), rifampin (n 4), and
pyrazinamide (n 2).
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difference in exposure to isoniazid in these two groups. The inter-
quartile OR for a positive culture at week 8 associated with an
increase in isoniazid C2 h from the 25th percentile (0.9 mg/liter,
see Table 2) to the 75th percentile of isoniazid C2 h values (2.2
mg/liter, Table 2) was not significantly lower than 1 (interquartile
OR, 0.88; 95% confidence interval [CI] 0.39 to 1.96). Similarly,
plasma concentrations were not significantly related to culture
results at week 4 (Table 3, upper part). The two patients with a
positive culture at week 24/32 had higher C2 h for the three drugs
than the patients with a negative culture (data not shown). Oddly,
four patients had a positive culture at week 8 or 24/32 after a
negative culture at week 4 or 8.
In view of the size of the study and the good treatment response
in the cohort, culture conversion at 8 weeks seemed less useful as a
measure of treatment response that would reveal possible deter-
minants of response. In a post hoc analysis, treatment responsewas
defined as “poor” if patients had at least one positive culture at
either week 4, 8, or 24/32. This analysis also prevented inappro-
priate classification of patients who had inconsistent results of
consecutive cultures (n  4, see above). In univariate post hoc
analyses, size of extensive lesions (OR for lesions 9 vertebrae
versus lesions  5 vertebrae, 3.94; 95% CI  1.20 to 12.98), iso-
niazid C2 h (interquartile OR, 0.58; 95% CI  0.35 to 0.96) and
pyrazinamideC2 h (interquartile OR, 0.59; 95%CI 0.37 to 0.93)
were significantly associated with the occurrence of at least one
positive culture at either week 4, 8, or 24/32. Also, patients in the
poor response group had very low plasma concentrations for two
or more drugs more frequently than the good response group
(18%versus 6%, P 0.04).C2 h values of rifampin and theMR for
isoniazid were not significantly related to treatment response.
Age, DM, HIV, prior TB treatment, sputum microscopy, and M.
tuberculosis Beijing genotype were also unrelated to response. In
multivariate analysis, size of extensive lesions (OR for lesions 9
vertebrae versus lesions  5 vertebrae, 6.30; 95% CI  1.25 to
31.87; P  0.01) and pyrazinamide C2 h (adjusted interquartile
OR, 0.33; 95% CI  0.13 to 0.80; P  0.01) were the only inde-
pendent predictors of treatment response.
DISCUSSION
This is one of relatively few studies that examined pharmacokinet-
ics and pharmacodynamics in patients with plasma concentration
samples of three antituberculosis drugs. In concordance with
other studies (1, 3, 5, 13), we observed large interindividual vari-
ability in plasma concentrations of TB drugs. Many patients had
TABLE 3 Relation between antituberculosis drug plasma concentrations and culture results at weeks 4 and 8a
Characteristicb
GM (IQR)
OR (95% CI)c for
positive culturePositive culture Negative culture
Wk 4 (n) 56 108
Isoniazid C2 h (mg/liter) 1.3 (0.9–2.2) 1.5 (1.0–2.2) 0.76 (0.49–1.18)*
Rifampin C2 h (mg/liter) 6.5 (5.1–10.8) 6.7 (4.8–11.8) 0.95 (0.66–1.36)*
Pyrazinamide C2 h (mg/liter) 35.4 (31.8–40.9) 37.0 (33.2–41.5) 0.80 (0.55–1.15)*
Low plasma concentrations
No drug 5 (36) 9 (64) 1.00
One drug 18 (35) 34 (65) 0.95 (0.28–3.27)
Two drugs 21 (37) 36 (63) 1.05 (0.31–3.55)
All three drugs 12 (29) 29 (71) 0.75 (0.21–2.69)
Very low plasma concentrations
No drug 24 (33) 49 (67) 1.00
One drug 23 (30) 53 (70) 0.89 (0.44–1.77)
Two drugs 8 (57) 6 (43) 2.72 (0.85–8.73)
All three drugs 1 (100) 0 (0) NA
Wk 8 (n) 11 142
Isoniazid C2 h (mg/liter) 1.3 (0.9–2.4) 1.4 (0.9–2.2) 0.88 (0.39–1.96)*
Rifampin C2 h (mg/liter) 6.5 (6.1–12.1) 6.8 (5.0–11.7) 0.95 (0.47–1.90)*
Pyrazinamide C2 h (mg/liter) 38.5 (34.0–44.6) 36.5 (32.4–41.0) 1.38 (0.65–2.93)*
Low plasma concentrations
No drug 2 (15) 11 (85) 1.00
One drug 3 (6) 46 (94) 0.36 (0.05–2.41)
Two drugs 4 (7) 50 (93) 0.44 (0.07–2.71)
All three drugs 2 (5) 35 (95) 0.31 (0.04–2.50)
Very low plasma concentrations
No drug 5 (7) 65 (93) 1.00
One drug 4 (6) 64 (94) 0.81 (0.21–3.16)
Two drugs 2 (14) 12 (86) 2.17 (0.38–12.49)
All three drugs 0 (0) 1 (100) NA
a Data are presented as the GM (IQR) or number (percentage) unless stated otherwise in column 1. Pharmacokinetic parameters were log transformed. OR, odds ratio; CI,
confidence interval; C2 h, plasma concentration 2 h after dose administration; NA, not assessed.
b For “low plasma concentrations,” isoniazid C2 h at3 mg/liter, rifampin C2 h at8 mg/liter, and pyrazinamide C2 h at35 mg/liter were considered low. For “very low plasma
concentrations,” isoniazid C2 h at1.5 mg/liter, rifampin C2 h at4 mg/liter, and pyrazinamide C2 h at20 mg/liter were considered very low. “No drug” served as a reference
category.
c *, That is, the OR for an interquartile range increase in C2 h, i.e., an increase in C2 h values from the 25th percentile to the 75th percentile of observed C2 h values (interquartile
OR), based on continuous drug concentration data.
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drug concentrations below reference values, despite administra-
tion of antituberculosis drug dosages through daily DOT. The
frequently observed low isoniazid concentrations were probably
the result of a majority of fast acetylators in our cohort, as ex-
pected in an Asian population (25, 26). In addition, in line with a
recent publication, we found lower isoniazid concentrations in
lower weight bands (27). Remarkably, the C2 h values of the dif-
ferent drugs were significantly correlated to each other, indicating
that patients with a low plasma concentration of one drug are also
at risk of having low plasma concentrations of the other drugs.
Treatment response was generally good. After 8 weeks, only
7% of the patients had a positive culture, much less compared to
another recent study in Indonesia, which found that 17 to 18% of
patients had a positive culture at 2months (28). Our primary data
analysis showed no relationship between C2 h of the three drugs
and culture conversion at 8 weeks, the only currently accepted
biomarker of sterilizing activity (22). Plasma drug concentrations
were neither significantly associated with culture results at week 4.
The post hoc data analysis suggests that only low plasma pyrazin-
amide concentrationsmay contribute to poor treatment response,
regardless of prior TB treatment, DM, or HIV status, and sputum
microscopy at baseline. It should be realized that this post hoc
analysis was not planned in advance, it used a nonvalidated com-
posite endpoint, and the findings are not supported by the week 4
orweek 8 associationswhich comprise the bulk of the events in the
composite endpoint. Nevertheless, the relevance of low pyrazin-
amide concentrations in this post hoc analysis would be consistent
with findings from two recently published studies (3, 4). Thera-
peutic drugmonitoring could identify patients whowould benefit
from pyrazinamide dose adjustments, but this is not feasible in
developing countries at this time. Another possibility for achiev-
ing higher drug levels of pyrazinamide is to increase the standard
doses of this drug. Recent studies in animal and in vitro models
have revealed that the use of pyrazinamide doses higher than those
currently used could increase the efficacy of pyrazinamide and
lead to better outcomes (29, 30), but experience from the past
indicated that higher doses of pyrazinamide are associated with
more hepatotoxicity. Clinical studies that investigate the efficacy
of these higher doses versus potential adverse events are war-
ranted.
Given the available data on relationships between rifampin
concentrations and response (31–33), the belief that the current
rifampin dose is at the lower end of the dose-response curve (34),
and the anticipated large interindividual variability in rifampin
pharmacokinetics, we expected rifampin plasma concentrations
to be related to treatment response as well. In addition, Pasipano-
dya showed that isoniazid acetylation-defined pharmacokinetic
variability was associated with microbiological outcome (17). In
the present study, these assumptions could not be confirmed. A
first explanation could be that it is not the C2 h or Cmax of the TB
drugs that is related to response, but the total drug exposure
(AUC). However, according to Jayaram et al. both AUC and Cmax
show a good correlationwith response, both for rifampin (32) and
isoniazid (35). In addition, these parameters are often strongly
related as demonstrated in this and other studies (6, 36, 37). As a
second explanation,C2 h was used as a surrogate ofCmax instead of
using a precisely estimated Cmax derived from repeated sampling
at different time points. Nevertheless, C2 h correlated well with
Cmax and/or AUC in this and other studies (13). A third explana-
tion could be that it is not the Cmax or AUC that is related to
response, but the Cmax/MIC or AUC/MIC. However, the MIC for
the various drugs was not determined. Fourth, response to rifam-
pin may better correlate to protein-unbound (free) concentra-
tions than to total (protein-unbound plus bound) concentrations
(38). Fifth, concentrations would ideally bemeasured at the target
locations, e.g., in the epithelial lining fluid instead of in plasma.
Sixth, it should be acknowledged that many factors determine
response in an individual patient apart from drug related factors,
such as patient and bacterial factors. In this complex interplay
with a limited number of participants wemay not expect pharma-
cokinetic factors to be dominant. Finally, the statistical approach
used to find associations between drug concentrations and re-
sponse may be relevant. We used conventional, well-accepted lo-
gistic regression analyses resulting in ORs. A limitation of this
method is that it does not account for the combined effects of the
drugs in the regimen.We tried to solve this by evaluating the effect
of the number of drugs with low plasma concentrations on treat-
ment response, using cutoff values based on average (population)
pharmacokinetic data.
Davies et al. argued that bacteriological biomarkers are likely to
be the most directly relevant pharmacodynamic response during
the treatment of TB (39). In a recent comprehensive evaluation of
clinical trials a strong relation was shown between 2-month and
3-month culture result and long-termoutcome (40). Culture con-
version after 2 months of treatment is the only currently accepted
biomarker of sterilizing activity (22), but due to the size of the
study and the good response rate this measure seemed less useful
to identify determinants of treatment response. It should be noted
that our post hoc definition of treatment response—being “poor”
if patients had at least one positive culture during treatment—is
not well validated as a surrogate parameter of treatment response.
Time to culture conversion might have been a better measure of
treatment response, but this could not be analyzed since cultures
were only sampled three times. Another limitation of this study is
that we measured TB drug concentrations just once during treat-
ment and that we only used a single sample at 2 h postdose to
estimate Cmax. Furthermore,M. tuberculosis Beijing genotype and
chest X-ray abnormalities as possible determinants of response
were not assessed in a subset of patients. The cutoff value of 1.5
regarding the MR for isoniazid, to differentiate between fast and
slowmetabolizers, was developed for plasma concentrations sam-
pled at 3 h postdose, instead of 2 h. This could have led to a
misclassification of patients.
In conclusion, we showed that low plasma concentrations of
isoniazid, rifampin, and pyrazinamide occurred inmany patients,
even with DOT strategy. Most patients had a good treatment out-
come despite these low drug concentrations. No association was
shown between plasma concentrations and culture results at 4 and
8 weeks of treatment. Post hoc analysis showed that patients with
low plasma pyrazinamide concentrations were at risk of at least
one positive culture at weeks 4, 8, or 24/32. The same applied to
patients with large lesions on chest X-ray. Dose adjustment or the
use of higher standard doses of pyrazinamide might be beneficial
for certain patients to improve treatment outcome.
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